Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Completed 1

Sponsor Class

OTHER 1

Study Type

Interventional 1

Sponsor

Cancer Type

Classical hematology 1

Conditions

Ovarian Neoplasms 2Squamous Cell Carcinoma of Head and Neck 1Small Cell Lung Carcinoma 1Prostatic Neoplasms 1Hereditary Breast and Ovarian Cancer Syndrome 1Fanconi Anemia 1Endometrial Neoplasms 1Breast Neoplasms 1

Interventions

fludarabine phosphate 4Cyclophosphamide 4Busulfan 3Antilymphocyte Serum 3fludarabine 2Peripheral Blood Stem Cell Transplantation 2Methylprednisolone 2Granulocyte Colony-Stimulating Factor 2Filgrastim 2thymoglobulin 1sargramostim 1prexasertib 1Tacrolimus 1Stem Cell Transplantation 1Radiotherapy 1Quercetin 1Mycophenolic Acid 1Melphalan 1Dietary Supplements 1Cord Blood Stem Cell Transplantation 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Phase 2 × Fanconi Anemia × prexasertib × Clear all
NCT02873975 2022-10-21

A Study of LY2606368 (Prexasertib) in Patients With Solid Tumors With Replicative Stress or Homologous Repair Deficiency

Dana-Farber Cancer Institute

Phase 2 Completed
27 enrolled 13 charts
Classical hematology

Fanconi Anemia

Data powered by HemOnc (CC BY 4.0) Colophon âš¡